Short Communication - Asian Journal of Biomedical and Pharmaceutical Sciences (2022) Volume 12, Issue 93

Methodological review on direct?acting oral anticoagulants

Vitamin K bad guys, like warfarin, have been the anticoagulants of decision for a long time for patients with AF and other thrombotic conditions. The presentation of direct oral anticoagulants (DOACs) as options addresses a meaningful step forward in anticoagulation. DOACs have been viewed as protected and compelling as vitamin K adversaries in randomized, controlled preliminaries for stroke counteraction in AF and the administration of venous thromboembolism, with certifiable information showing comparable results. With the accessibility of a few specialists, choosing the most suitable DOAC can challenge. Benefits of DOACs incorporate unsurprising pharmacokinetics, scarcely any medication drug associations, and low checking necessities.

Author(s): Sakshi Vaidya

Abstract Full Text PDF